Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | COVID-19 | Research

Association of serum uric acid levels with COVID-19 severity

Authors: Fang Hu, Yifan Guo, Jianghong Lin, Yingjuan Zeng, Juan Wang, Man Li, Li Cong

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Aims

Hyperuricemia has attracted increasing attention. However, limited concern has been paid to the potential dangers of lowering serum uric acid (SUA). We observed lower levels of SUA in patients with COVID-19. Therefore, we aim to explore whether patients with COVID-19 had SUA lower than normal and the relationship of SUA and the severity of COVID-19.

Methods

This was a case–control study based on 91 cases with COVID-19 and 273 age- and sex-matched healthy control subjects. We first compared SUA levels and uric acid/creatinine (UA/Cr) ratio between patients with COVID-19 and the healthy controls. Then, we examined the association of SUA levels and UA/Cr ratios with COVID-19 severity in COVID-19 cases only, defined according to the fifth edition of China’s Diagnosis and Treatment Guidelines of COVID-19.

Results

SUA levels in patients with COVID-19 were 2.59% lower, UA/Cr ratios 6.06% lower at admission compared with healthy controls. In sex stratified analysis, levels of SUA and UA/Cr were lower in male patients with COVID-19 while only level of SUA was lower in female patients with COVID-19. Moreover, SUA and UA/Cr values were 4.27 and 8.23% lower in the severe group than that in the moderate group among male COVID-19 patients. Bivariate and partial correlations analysis showed negative correlations between SUA or UA/Cr ratio and COVID-19 after adjusting for age, sex, BMI and eGFR. A multiple linear regression analysis showed that SARS-CoV-2 infection and male sex were independent risk factors associated with lower SUA levels. Male patients with COVID-19 accompanied by low SUA levels had higher risk of developing severe symptoms than those with high SUA levels (incidence rate ratio: 4.05; 95% CI:1.11, 14.72) at admission. Comparing SUA and UA/Cr ratio at three time points (admission, discharge, and follow-up), we found that male patients experienced severe symptoms had lower SUA and UA/Cr ratio levels comparing to moderate patients, but no significant difference between three time points. On the contrary, female patients had lower SUA and UA/Cr ratio at discharge than those at admission, but no significant difference of SUA and UA/Cr ratio between moderate and severe group.

Conclusion

Patients with COVID-19 had SUA and UA/Cr values lower than normal at admission. Male COVID-19 patients with low SUA levels had a significantly higher crude risk of developing severe symptoms than those with high SUA levels. During disease aggravation, the level of SUA gradually decreased until discharge. At the follow-up exam, the level of SUA was similar to the levels at admission.
Appendix
Available only for authorised users
Literature
1.
go back to reference Weekly operational update on COVID-19 - 8 March 2021, 2021. Weekly operational update on COVID-19 - 8 March 2021, 2021.
2.
go back to reference Leigh R, Proud D. Virus-induced modulation of lower airway diseases: pathogenesis and pharmacologic approaches to treatment. Pharmacol Ther. 2015;148:185–98.CrossRef Leigh R, Proud D. Virus-induced modulation of lower airway diseases: pathogenesis and pharmacologic approaches to treatment. Pharmacol Ther. 2015;148:185–98.CrossRef
3.
go back to reference Akaike T, Suga M, Maeda H. Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. Proc Soc Exp Biol Med. 1998;217:64–73.CrossRef Akaike T, Suga M, Maeda H. Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. Proc Soc Exp Biol Med. 1998;217:64–73.CrossRef
4.
go back to reference Papi A, Contoli M, Gasparini P, et al. Role of xanthine oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. J Biol Chem. 2008;283:28595–606.CrossRef Papi A, Contoli M, Gasparini P, et al. Role of xanthine oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. J Biol Chem. 2008;283:28595–606.CrossRef
5.
go back to reference Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858–62.CrossRef Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858–62.CrossRef
6.
go back to reference Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001;38:365–71.CrossRef Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001;38:365–71.CrossRef
7.
go back to reference Waring WS, McKnight JA, Webb DJ, et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006;55:3127–32.CrossRef Waring WS, McKnight JA, Webb DJ, et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006;55:3127–32.CrossRef
9.
go back to reference Li S, Shao M, Tang B, et al. The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study. Oncotarget. 2017;8:2816–24.CrossRef Li S, Shao M, Tang B, et al. The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study. Oncotarget. 2017;8:2816–24.CrossRef
10.
go back to reference Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.CrossRef Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.CrossRef
11.
go back to reference Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11:240.CrossRef Gaffo AL, Edwards NL, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11:240.CrossRef
12.
go back to reference Sluijs I, Beulens JW, van der D.L. A, et al. Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr. 2013;143:80–5.CrossRef Sluijs I, Beulens JW, van der D.L. A, et al. Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr. 2013;143:80–5.CrossRef
13.
go back to reference Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric Acid cause type 2 diabetes? Endocr Rev. 2009;30:96–116.CrossRef Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric Acid cause type 2 diabetes? Endocr Rev. 2009;30:96–116.CrossRef
14.
go back to reference Virdis A, Masi S, Casiglia E, et al. Identification of the uric Acid thresholds predicting an increased Total and cardiovascular mortality over 20 years. Hypertension. 2020;75:302–8.CrossRef Virdis A, Masi S, Casiglia E, et al. Identification of the uric Acid thresholds predicting an increased Total and cardiovascular mortality over 20 years. Hypertension. 2020;75:302–8.CrossRef
15.
go back to reference Ortiz A, Massy ZA, Fliser D, et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol. 2011;8:141–50.CrossRef Ortiz A, Massy ZA, Fliser D, et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol. 2011;8:141–50.CrossRef
16.
go back to reference Tseng WC, Chen YT, Ou SM, et al. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment, J AM HEART ASSOC 7; 2018.CrossRef Tseng WC, Chen YT, Ou SM, et al. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment, J AM HEART ASSOC 7; 2018.CrossRef
17.
go back to reference Odden MC, Amadu AR, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and nutrition examination survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis. 2014;64:550–7.CrossRef Odden MC, Amadu AR, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and nutrition examination survey (NHANES) 1988–1994 and 1999–2002. Am J Kidney Dis. 2014;64:550–7.CrossRef
18.
go back to reference Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma Urate, cancer incidence, and all-cause mortality: a Mendelian randomization study. Clin Chem. 2017;63:1151–60.CrossRef Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma Urate, cancer incidence, and all-cause mortality: a Mendelian randomization study. Clin Chem. 2017;63:1151–60.CrossRef
20.
go back to reference Liu J, Li M, Wang X, et al. Serum uric acid levels in patients with infections of central nervous system. Acta Neurol Belg. 2016;116:303–8.CrossRef Liu J, Li M, Wang X, et al. Serum uric acid levels in patients with infections of central nervous system. Acta Neurol Belg. 2016;116:303–8.CrossRef
23.
go back to reference Allison SJ. Chronic kidney disease: the CKD-EPI equation--accurately stratifying risk in CKD. Nat Rev Nephrol. 2012;8:371.CrossRef Allison SJ. Chronic kidney disease: the CKD-EPI equation--accurately stratifying risk in CKD. Nat Rev Nephrol. 2012;8:371.CrossRef
24.
go back to reference Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19:1331–6.CrossRef Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19:1331–6.CrossRef
25.
go back to reference Du N, Xu D, Hou X, et al. Inverse association between serum uric Acid levels and Alzheimer's disease risk. Mol Neurobiol. 2016;53:2594–9.CrossRef Du N, Xu D, Hou X, et al. Inverse association between serum uric Acid levels and Alzheimer's disease risk. Mol Neurobiol. 2016;53:2594–9.CrossRef
26.
go back to reference Collazos J, Blanco MS, Guerra E, et al. Sequential evaluation of serum urate concentrations in AIDS patients with infections of the central nervous system. Clin Chem Lab Med. 2000;38:1293–6.CrossRef Collazos J, Blanco MS, Guerra E, et al. Sequential evaluation of serum urate concentrations in AIDS patients with infections of the central nervous system. Clin Chem Lab Med. 2000;38:1293–6.CrossRef
27.
go back to reference Dickerhof N, Turner R, Khalilova I, et al. Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease. J Cyst Fibros. 2017;16:214–21.CrossRef Dickerhof N, Turner R, Khalilova I, et al. Oxidized glutathione and uric acid as biomarkers of early cystic fibrosis lung disease. J Cyst Fibros. 2017;16:214–21.CrossRef
28.
go back to reference Montero-Chacón LB, Padilla-Cuadra JI, Chiou SH, Torrealba-Acosta G. High-density lipoprotein, Mean Platelet Volume, and Uric Acid as Biomarkers for Outcomes in Patients with sepsis: an observational study. J Intensive Care Med. 2020;35(7):636–42. https://doi.org/10.1177/0885066618772825. Epub 2018 May 2. Montero-Chacón LB, Padilla-Cuadra JI, Chiou SH, Torrealba-Acosta G. High-density lipoprotein, Mean Platelet Volume, and Uric Acid as Biomarkers for Outcomes in Patients with sepsis: an observational study. J Intensive Care Med. 2020;35(7):636–42. https://​doi.​org/​10.​1177/​0885066618772825​. Epub 2018 May 2.
29.
go back to reference Jing LJ, Liu J, Chen Y, et al. Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Res Clin Pract. 2020;167:108351.CrossRef Jing LJ, Liu J, Chen Y, et al. Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Res Clin Pract. 2020;167:108351.CrossRef
32.
go back to reference Antonioli L, Pacher P, Vizi ES, et al. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355–67.CrossRef Antonioli L, Pacher P, Vizi ES, et al. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355–67.CrossRef
33.
go back to reference Macaluso MP. Testicular factors (testosterone, hyaluronidase) and uric acid. Rev Rhum Mal Osteoartic. 1959;26:106–12.PubMed Macaluso MP. Testicular factors (testosterone, hyaluronidase) and uric acid. Rev Rhum Mal Osteoartic. 1959;26:106–12.PubMed
34.
go back to reference Liu Y, Lin Z, Sheng C, et al. The prevalence of thyroid nodules in Northwest China and its correlation with metabolic parameters and uric acid. Oncotarget. 2017;8:41555–62.CrossRef Liu Y, Lin Z, Sheng C, et al. The prevalence of thyroid nodules in Northwest China and its correlation with metabolic parameters and uric acid. Oncotarget. 2017;8:41555–62.CrossRef
35.
go back to reference Zhang X, Zhu C, Gao J, et al. Gender difference in the relationship between serum uric acid reduction and improvement in body fat distribution after laparoscopic sleeve gastrectomy in Chinese obese patients: a 6-month follow-up. Lipids Health Dis. 2018;17:288.CrossRef Zhang X, Zhu C, Gao J, et al. Gender difference in the relationship between serum uric acid reduction and improvement in body fat distribution after laparoscopic sleeve gastrectomy in Chinese obese patients: a 6-month follow-up. Lipids Health Dis. 2018;17:288.CrossRef
Metadata
Title
Association of serum uric acid levels with COVID-19 severity
Authors
Fang Hu
Yifan Guo
Jianghong Lin
Yingjuan Zeng
Juan Wang
Man Li
Li Cong
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00745-2

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.